BC
ANIK icon

Barrett & Company’s Anika Therapeutics ANIK Stock Holding History

Barrett & Company’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-260
Closed -$2.44K – 662
2025
Q3 		$2.44K Hold
260
– – ﹤0.01% 573
2025
Q2 		$2.75K Hold
260
– – ﹤0.01% 566
2025
Q1 		$3.91K Hold
260
– – ﹤0.01% 518
2024
Q4 		$4.28K Hold
260
– – ﹤0.01% 509
2024
Q3 		$6.42K Hold
260
– – ﹤0.01% 461
2024
Q2 		$6.59K Hold
260
– – ﹤0.01% 467
2024
Q1 		$6.6K Hold
260
– – ﹤0.01% 467
2023
Q4 		$5.89K Hold
260
– – ﹤0.01% 459
2023
Q3 		$4.84K Hold
260
– – ﹤0.01% 484
2023
Q2 		$6.75K Hold
260
– – ﹤0.01% 445
2023
Q1 		$7.47K Hold
260
– – ﹤0.01% 411
2022
Q4 		$7.7K Hold
260
– – 0.01% 405
2022
Q3 		$7.7K Buy
+260
New +$5.98K 0.01% 405

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barrett & Company's ANIK Position: Q4 2025 in Review

Barrett & Company sold out of Anika Therapeutics (ANIK) in Q4 2025, closing a stake of 260 shares — an estimated $2.44K sold.

Barrett & Company first reported a position in ANIK in Q3 2022 and held it in 13 quarters. The position peaked at $7.7K in Q4 2022. 126 funds tracked by Wall St. Rank hold ANIK as of Q4 2025.

  • Barrett & Company reported no remaining Anika Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Barrett & Company sold 260 Anika Therapeutics shares in Q4 2025, an estimated $2.44K.
  • Barrett & Company first reported a position in Anika Therapeutics in Q3 2022 and held it in 13 quarters.
  • Barrett & Company's Anika Therapeutics position peaked at $7.7K in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2025.

Based on Barrett & Company's 13F filing for Q4 2025, filed 28 Jan 2026.